{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 118 of 128', 'The destruction process must ensure confidentiality of data and must be done in accordance', 'with local regulatory requirements.', 'For archiving purposes, each investigator will be supplied with an electronic copy of the', 'eCRFs and ePRO data for all screened and randomised subjects enrolled at the trial site. This', 'is done after completion of the trial and before access to the eCRF/ePRO is revoked. Audit', 'trail information will be included. eCRFs and ePRO data must be available for inspection by', 'authorised representatives from LEO, from regulatory authorities and/or IRBs/IECs.', 'Appendix 3E: Registration, reporting and publication policy', 'Trial disclosure', 'LEO is committed to be transparent with respect to its clinical trials.', 'Basic information of this clinical trial will be registered in the global data registry,', 'www.ClinicalTrials.gov before the first subject enters into the trial. The trial may also become', 'registered in other online data registries, according to applicable law and regulations.', 'Results of this clinical trial will be posted on the corporate website of LEO in accordance with', 'our Position on Public Access to Clinical Trial Information no later than 12 months after trial', 'completion. Trial results may also become reported in www.ClinicalTrials.gov,', 'www.clinicaltrialsregister.eu and national data registries in accordance with applicable law', 'and regulations after clinical trial completion or premature termination.', 'LEO may also provide researchers access to anonymised patient level data for further', 'research. Publication and access will be in accordance with the Position on Public Access to', 'Clinical Trials which can be found on the LEO website.', 'Publications', 'The investigator shall be entitled to make publications of the results generated by investigator', 'in accordance with the process described here.', 'A', 'multi-centre publication will be submitted for publication within 18 months after the', 'clinical trial has been completed or terminated at all trial sites and all data have been received,', 'defined as database lock of the clinical trial. After such multi-centre publication is made', 'public, or if no multi-centre publication has been submitted with the above-described', 'deadline, the investigator shall have the right to publish the results from the clinical trial', 'generated by the investigator, subject to the following notice requirements:']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 119 of 128', 'Prior to submission for publication or presenting a manuscript relating to the clinical trial, the', 'investigator shall provide to LEO a copy of all such manuscripts and/or presentations. LEO', 'shall have rights to review and comment. The investigator shall consider comments provided', 'by LEO but is not required to modify the manuscript and/or presentation based on such', 'comments, provided, however, that the investigator upon the request of LEO removes any', 'confidential information (other than results generated by the investigator) prior to submitting', 'or presenting the manuscripts. The investigator shall, upon the request of LEO withhold the', 'publication or presentation to allow LEO to protect its inventions and other intellectual', 'property rights described in any such manuscripts.', \"In case no multi-centre publication has been made public at the time of investigator's\", 'notification of an independent publication to LEO, LEO and the writing group may also delay', 'the publication or presentation if the manuscript is deemed to harm the ongoing multi-centre', 'publication.', 'In case of publications made by the investigator after the first multi-centre publication has', 'been published, the above-mentioned requirements must still be followed.', 'Any publication must comply with Good Publication Practice (GPP3) standards.', 'LEO complies with GPP3 standards and the recommendations from the International', 'Committee of Medical Journal Editors. LEO complies with the positions of the International', 'Federation of Pharmaceutical Manufacturers & Associations (IFPMA), European Federation', 'of Pharmaceutical Industries and Associations (EFPIA), Japan Pharmaceutical Manufacturers', 'Association (JPMA), Pharmaceutical Research and Manufacturers of America (PhRMA), and', 'the joint position statement by the American Medical Writers Association (AMWA), the', 'European Medical Writers Association (EMWA), and the International Society for Medical', 'Publication Professionals (ISMPP) on disclosure of information about clinical trials, trial', 'results and authorship. LEO also follows the CONSORT reporting guidelines (12).', 'Appendix 3F: Insurance', 'LEO has taken out relevant insurances covering the subjects in the present clinical trial in', 'accordance with applicable laws and regulations.', 'Appendix 3G: Financial disclosure', 'Investigators will provide LEO with sufficient, accurate financial information as requested to', 'allow LEO to submit complete and accurate financial certification or disclosure statements to', 'the appropriate regulatory authorities. Investigators are responsible for providing information']\n\n###\n\n", "completion": "END"}